IGF2 and cancer: This suggests that, while developmental growth is mediated through the insulin-like growth factor 1 receptor (IGF-1R), IGF-II/IR-A signaling can provide an additional or alternate pathway to stimulate cell growth, allowing cancer cells to become resistant to treatments targeting the IGF-1R [6,7,10].